Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;69(3):192-206.
doi: 10.1016/j.curtheres.2008.06.002.

Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study

Giuseppe Rossetti  1 , Samuele Pizzocri  1 , Francesco Brasca  1 , Marta Pozzi  1 , Laura M Beltrami  1 , Giovanni B Bolla  2 , Roberta Famiani  1 , Barbara Caimi  1 , Stefano Omboni  3 , Fabio Magrini  2 , Stefano Carugo  1
Affiliations

Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study

Giuseppe Rossetti et al. Curr Ther Res Clin Exp. 2008 Jun.

Erratum in

  • Curr Ther Res Clin Exp. 2008 Aug;69(4):378-9

Abstract

Background: Dihydropyridine calcium antagonists are largely employed for the treatment of hypertension, coronary heart disease, and heart failure.

Objective: The aim of our study was to compare the antihypertensive effect of the dihydropyridine calcium antagonists barnidipine and amlodipine.

Methods: This was a 24-week, randomized, open-label, pilot study. Consecutive treatment-naive patients with grade I or II essential hypertension (office sitting systolic blood pressure [BP] of 140-179 mm Hg and diastolic BP of 90-109 mm Hg) were enrolled. The primary end points were the effect of treatment with either barnidipine 10 mg or amlodipine 5 mg once daily on office and ambulatory BP, left ventricular mass index (LVMI), and markers of cardiac damage, serum procollagen type I C-terminal propeptide, and plasma amino-terminal pro-B-type natriuretic peptide concentrations. Patients were assessed at enrollment, and 12 and 24 weeks. During each visit, the prevalence of adverse events (AEs) was also monitored using spontaneous reporting, patient interview, and physical examination, the relationship to study drug being determined by the investigators. Compliance with treatment was assessed at each study visit by counting returned tablets.

Results: Thirty eligible patients (20 men, 10 women; mean [SD] age, 47 [12] years) were included in the study; all patients completed the 24 weeks of study treatment. Twelve weeks after randomization, 6 patients in the amlodipine group had their dose doubled to 10 mg due to inadequate BP control. Mean BP reductions at study end were not significantly different between the barnidipine and amlodipine groups (office BP, -10.3/-9.4 vs -16.6/-9.1 mm Hg; ambulatory BP, 9.4/6.4 vs 8.1/5.1 mm Hg). Reductions in LVMI and markers of cardiac damage were not significantly different between the 2 groups. Significantly more patients in the amlodipine group reported drug-related AEs compared with those in the barnidipine group (9 [60%] vs 2 [13%]; P < 0.05).

Conclusion: In this small sample of treatment-naive hypertensive patients, the antihypertensive effect of barnidipine 10 mg once daily was not significantly different from that of amlodipine 5 to 10 mg once daily.

Keywords: ambulatory bloodpressure monitoring; amlodipine; barnidipine; essential hypertension; left ventricular mass index; smoothness index.

PubMed Disclaimer

References

    1. Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH) 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151–183. - PubMed
    1. Chobanian AV, Bakris GL, Black HR, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560–2572. [published correction appears in JAMA. 2003;290:197] - PubMed
    1. Mancia G, De Backer G, Dominiczak A, Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens. 2007;25:1105–1187. [published correction appears in J Hypertens. 2007;25:1749] - PubMed
    1. Chen K, Chiou CF, Plauschinat CA. Patient satisfaction with antihypertensive therapy. J Hum Hypertens. 2005;19:793–799. - PubMed
    1. Erkens JA, Panneman MM, Klungel OH. Differences in antihypertensive drug persistence associated with drug class and gender: A PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14:795–803. - PubMed